secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001564590-22-028003
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q2 revenue up 29% YoY to $38.5M; net loss widens to $47.7M, maintains 2022 outlook
--------------------------------------------------------------------------------

- Software revenue $30.0M (+25% YoY); drug discovery revenue $8.5M (+48% YoY).
- Net loss of $47.7M vs. $35.0M in Q2 2021; gross profit $17.1M (+43%).
- Cash, equivalents, and marketable securities ~$513M, down from $529M at March 31, 2022.
- IND for MALT1 inhibitor SGR-1505 cleared; Phase 1 trial in B-cell lymphoma expected Q4 2022.
- Maintains full-year 2022 guidance: total revenue $161M–$181M, software revenue $126M–$136M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000156459022028003/0001564590-22-028003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000156459022028003/sdgr-8k_20220804.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer